
Taylor Jenkins Reid is among the stars — on and off the page
Writing about new worlds is nothing new for American writer Taylor Jenkins Reid.
From 1950s Los Angeles in The Seven Husbands of Evelyn Hugo to the professional tennis circuit in Carrie Soto is Back, Reid's work peels the curtain back on unfamiliar ecosystems — and brings her readers along with her.
Reid's latest novel, Atmosphere, however, takes us out of this world, featuring women astronauts in the 1980s. She said it's been her hardest research challenge yet, but one she couldn't refuse.
"I only know how to write the stories that call to me," she said on Bookends with Mattea Roach. "An idea shows up and I get really into it and I think that'd be a really fun book to read. And then somehow, between that moment and finishing the book, I have to somehow become a person who could write that book."
Between studying the history of NASA, the stories of early women astronauts and learning how a space shuttle actually works, Reid set herself up for hours of research and conversations with Paul Dye, the now retired longest-serving flight director at NASA.
"I'm proud of actually completing [ Atmosphere ] because, to be honest, it was incredibly hard to write," she said.
"But I'm also just proud of the love story and I do hope that it finds its way to the people that need it and also the people who would just enjoy it."
Atmosphere is a love story in many ways — from the main character Joan's love for space and the stars, to her slow-burn romantic relationship with fellow astronaut Vanessa, and the strong bond she has with her niece, Frances.
The novel is thrilling from the start, when readers learn there's been an explosion on a space shuttle, and it bounces back and forth in time, sharing Joan's journey to being the voice of mission control on this fateful day — and what's at stake, both personally and professionally, when things don't go as planned.
"I really do see in Joan a sort of delayed coming of age story," said Reid. "This is a person who has gotten it all right. She did everything she was supposed to do.
"Now that she's achieved this thing that most people could never achieve, there's room for her to start asking herself some questions. And it's not just related to her sexuality. There are a lot of ways that Joan comes into herself throughout the course of the book."
A love story
Part of Joan's growth is becoming more sure of who she is, which is helped by the way she is loved by Vanessa, who is so confident and has such a strong understanding of herself.
"There is an attraction there that is not just about proximity, it's about the fact that Joan wants to be a person that Vanessa would like — and looking at Joan's self through the eyes of Vanessa feels really, really good.
"That is powerful enough to make Joan start asking herself certain questions that she hasn't asked."
It's similar for Vanessa, who also loves the fact that she is loved by Joan.
"This person who is so good and so kind, in Vanessa's eyes, thinks that Vanessa is good and kind and I think that is something that is worth Vanessa rearranging her whole life for."
While the backdrop of the 80s and the high-pressure work environment of NASA pose some challenges for the couple, Joan and Vanessa's love for each other isn't thrown into question or put in jeopardy.
They just have to figure out the best way to separate their private lives from their public ones, as some of the first female astronauts who are under intense scrutiny to perform well and be role models for younger generations.
The public vs. the private
Reid herself is no stranger to scrutiny — and she explores that theme in almost all of her novels.
She was catapulted into the public eye thanks to the breakout success of The Seven Husbands of Evelyn Hugo and Daisy Jones and the Six, which was also made into a TV show, and has since been a prominent literary figure.
"If I could just write books and nobody knew who I was as a person, that would be ideal for me," she said.
But even though she'd rather stay unknown, as time progresses, her relationship with fame has evolved.
"I like it when authors who I really admire talk about why they wrote the book and where it comes from," she said. "As a reader and as a fan, I am interested in these things."
She also loves the moments of connection when strangers share the parts of the books that have meant a lot to them.
Lately, she's been working on separating the public version of herself from the one she knows to be true.
"People can say whatever they're going to say about me. It could be the most lovely thing in the world. It could be terrible. It doesn't mean it's true about me."
Motherhood in writing and real life
Because for Reid, success is about being someone those close to her can be proud of — starting with her immediate family — her husband and her daughter, who inspires one of the relationships in Atmosphere.
By writing about Joan and her niece Frances, Reid was able to examine the bittersweet feeling of watching a child grow up from her own experience.
"Each stage is better than the last, but at the same time you miss the last one and you're looking forward to the next one," she said.
"I loved writing about that here. It felt really lovely to indulge that part of myself and I think the relationship between Joan and Frances is somewhat shaped by how good it felt to write about them."
In the acknowledgments for Atmosphere, Reid writes that her daughter's positive feedback and emotional response to the story was the most satisfying thing she's ever done creatively.
"I really want her to be proud of me," she said on Bookends. "I don't know that I [ever] wanted somebody to be proud of me in the way that I hope that she is."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
an hour ago
- CTV News
78th Annual Tony Awards recap
2024-2025 was Broadway's highest grossing season ever. CTV's Andria Case reports on the 78th annual Tony Awards.


Globe and Mail
2 hours ago
- Globe and Mail
Spinal Muscular Atrophy Pipeline Drugs Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight
"Spinal Muscular Atrophy Pipeline" Spinal Muscular Atrophy companies are Amniotics, Biohaven Pharmaceuticals, Hoffmann-La Roche, Amylon Therapeutics, Voyager Therapeutics, Catalyst Pharmaceuticals, CANbridge Pharmaceuticals Inc., Astellas Pharma, Alcyone Therapeutics, Exicure, AndroScience Corporation, Scholar Rock, NMD Pharma, Aurimed Pharma, Biogen, Hanugen Theraputics, and others. (Albany, USA) 'Spinal Muscular Atrophy Pipeline Insight, 2025″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market. The Spinal Muscular Atrophy clinical trials report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report: In March 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with spinal muscular atrophy (SMA) who are receiving an SMN-targeted treatment. The FDA will review the application under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2025. The FDA priority review designation conveys that the FDA has determined that if apitegromab is approved, it could offer significant improvement in the safety or effectiveness of treatment of the serious condition of SMA Spinal Muscular Atrophy Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years. Leading Spinal Muscular Atrophy companies working in the market are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others, are developing therapies for the Spinal Muscular Atrophy treatment Spinal Muscular Atrophy emerging therapies such as – ACTX-401, Apitegromab, GYM329, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years. In February 2025, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water. In January 2025, Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®). On April 2024, Hoffmann-La Roche announced a Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy On April 2024, Genentech announced results of a multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments. On April 2024, Biogen announced results of a study whose primary objective is to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C). On January 2024, Novartis announced results of a Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to < 18 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza®) or Risdiplam (Evrysdi®). On January 2024, NMD Pharma A/S announced results of a Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy On December 2023, Novartis announced results of a Long-term Safety Study in Brazilian Patients With a Confirmed Diagnosis of Spinal Muscular Atrophy (SMA) Treated With Onasemnogene Abeparvovec (Zolgensma®) – ARISER Study. On May 2023, Biogen announced results of a study whose primary objective is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA) Spinal Muscular Atrophy Overview Spinal Muscular Atrophy (SMA) is a rare genetic neuromuscular disorder that affects motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by mutations in the SMN1 (Survival Motor Neuron 1) gene, which results in reduced levels of the SMN protein essential for motor neuron survival. The severity of SMA varies, and it is classified into different types (SMA 0–4) based on age of onset and disease progression. Spinal Muscular Atrophy primarily affects voluntary muscles, particularly those involved in movement, breathing, and swallowing. Spinal Muscular Atrophy Symptoms range from severe muscle weakness in infancy (SMA Type 1, the most common and severe form) to milder symptoms with later onset (SMA Type 3 and 4). In severe cases, respiratory complications can be life-threatening. Spinal Muscular Atrophy Diagnosis is confirmed through genetic testing. While there is no cure, disease-modifying therapies like nusinersen (Spinraza), risdiplam (Evrysdi), and gene therapy with onasemnogene abeparvovec (Zolgensma) can improve motor function and survival. Supportive care, including physical therapy, respiratory support, and nutritional management, plays a crucial role in improving the quality of life. Spinal Muscular Atrophy Advancements in treatment and early intervention, especially through newborn screening, have significantly improved outcomes for individuals with SMA. Spinal Muscular Atrophy Pipeline Therapeutics Assessment DelveInsight's Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include: ACTX-401: Novartis Apitegromab: Scholar Rock GYM329: Roche And Many Others Spinal Muscular Atrophy Pipeline Analysis: The Spinal Muscular Atrophy pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment. Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies @ Spinal Muscular Atrophy Companies and Drugs Scope of Spinal Muscular Atrophy Pipeline Drug Insight Coverage: Global Key Spinal Muscular Atrophy Companies: Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers Table of Contents Spinal Muscular Atrophy Report Introduction Spinal Muscular Atrophy Executive Summary Spinal Muscular Atrophy Overview Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment Spinal Muscular Atrophy Pipeline Therapeutics Spinal Muscular Atrophy Late Stage Products (Phase II/III) Spinal Muscular Atrophy Mid Stage Products (Phase II) Spinal Muscular Atrophy Early Stage Products (Phase I) Spinal Muscular Atrophy Preclinical Stage Products Spinal Muscular Atrophy Therapeutics Assessment Spinal Muscular Atrophy Inactive Products Company-University Collaborations (Licensing/Partnering) Analysis Spinal Muscular Atrophy Key Companies Spinal Muscular Atrophy Key Products Spinal Muscular Atrophy Unmet Needs Spinal Muscular Atrophy Market Drivers and Barriers Spinal Muscular Atrophy Future Perspectives and Conclusion Spinal Muscular Atrophy Analyst Views Appendix About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:


Globe and Mail
3 hours ago
- Globe and Mail
Molecular Infectious Disease Testing: A Strategic Imperative in the Next Era of Diagnostic Innovation
"Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany)" The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. In a world increasingly shaped by precision medicine and real-time response to public health threats, Molecular Infectious Disease Testing has emerged as a critical force driving both clinical excellence and strategic business transformation. As healthcare systems, diagnostic developers, and life sciences firms recalibrate in the wake of global disruptions, this once-specialized segment now anchors a new paradigm of proactive, data-driven, and resilient healthcare. The Molecular Infectious Disease Testing Market is poised for significant expansion—powered by evolving pathogen landscapes, digital diagnostics, and next-gen sample-to-answer platforms. For C-suite leaders, this moment presents a rare convergence of public health necessity, commercial scalability, and long-term strategic advantage. Download PDF Brochure: Reframing Diagnostics: From Passive Detection to Intelligent Surveillance Historically, infectious disease diagnostics operated as reactive tools—used to confirm a clinical suspicion. Today, molecular testing reframes this narrative. It offers early detection, predictive analytics, and pathogen-level precision across clinical, commercial, and community settings. From hospital labs to point-of-care environments, molecular diagnostics enable providers to shift from treatment to prevention, aligning with global healthcare imperatives. Molecular platforms—driven by PCR, isothermal amplification, and CRISPR-based innovations—now deliver results in under an hour with laboratory-grade accuracy. This speed-accuracy fusion is not merely a clinical upgrade; it fundamentally redefines operational models for diagnostic providers, healthcare systems, and public health authorities. For enterprises invested in diagnostics, the value proposition is clear: real-time infectious disease visibility fuels smarter resource allocation, reduces hospital burden, and enhances patient outcomes, all while positioning stakeholders as architects of the next diagnostic frontier. Strategic Growth Catalysts: What's Driving Market Acceleration Several macro and micro factors coalesce to propel the Molecular Infectious Disease Testing Market into its next growth phase: 1. Expanding Disease Burden and Antimicrobial Resistance (AMR) The global burden of infectious diseases remains persistent, with resurging pathogens (e.g., RSV, TB, dengue) and emerging zoonotic threats challenging static diagnostic infrastructure. Molecular tools provide the agility and specificity needed to differentiate bacterial from viral infections, a critical step in curbing unnecessary antibiotic use and mitigating AMR. 2. Decentralization of Diagnostics The COVID-19 era taught healthcare an invaluable lesson: decentralization saves lives. With the rise of near-patient and at-home molecular testing platforms, diagnostics are no longer tethered to centralized labs. Enterprises that adapt their go-to-market strategies to support distributed testing architectures —via partnerships with retail clinics, mobile labs, or remote monitoring—will unlock new access points and patient touchpoints. 3. Integration with Digital Health and AI AI and machine learning now bolster molecular diagnostics by enhancing pathogen detection accuracy, analyzing multi-pathogen panels, and predicting outbreak trajectories. Diagnostic systems integrated with EHRs and cloud platforms empower real-time clinical decisions, operational benchmarking, and population-level insights. This digital-molecular fusion presents fertile ground for healthcare innovation. 4. Policy and Funding Momentum Across North America, Europe, and APAC, health authorities are expanding reimbursement codes, issuing preparedness grants, and incentivizing rapid diagnostics in low-resource and high-risk settings. This public-private alignment creates a robust financial scaffold that enables enterprise-level scaling of molecular platforms. Real-World Applications: Impact Across Ecosystems Molecular infectious disease testing is already reshaping operations in high-stakes environments: - Hospitals and Health Systems Rapid syndromic panels reduce patient length of stay, enhance cohorting strategies, and improve antimicrobial stewardship. Molecular diagnostics empower ID specialists to tailor therapy within hours, leading to better outcomes and lower costs per diagnosis. - Pharmaceutical R&D Clinical trial timelines for anti-infectives depend on early, accurate identification of pathogens. Molecular testing accelerates patient enrollment and pathogen profiling, de-risking development pipelines and expediting time-to-market for novel therapeutics. - Public Health and Biosecurity Central and regional agencies are embedding molecular testing into surveillance systems. These platforms offer real-time outbreak detection and genomic surveillance to preempt community spread, identify variants, and inform containment protocols. - Travel, Defense, and Corporate Health Airports, military bases, and corporate campuses now deploy rapid molecular testing for pre-entry screening and ongoing surveillance. This enables safe continuity of operations in mission-critical sectors. Industry Trends and Long-Term Shifts: Preparing for 2030 The next five years will define the blueprint for molecular diagnostics—shaped by three dominant themes: 1. Platform Convergence The future is not single-pathogen but multiplexed and modular. Next-gen systems will support simultaneous detection of viral, bacterial, and fungal targets on customizable panels—driven by cloud-based upgrades and modular chemistry. 2. Global Accessibility Low- and middle-income countries (LMICs) represent a major growth frontier. Companies investing in affordable, ruggedized, solar-compatible molecular platforms stand to gain first-mover advantage in these underserved yet high-need markets. 3. Consumerization and At-Home Testing With rising health literacy and demand for convenience, molecular diagnostics will continue migrating into consumer channels, supported by e-commerce, telehealth integration, and mobile sample logistics. Strategic partnerships with digital health platforms will be crucial for brand relevance and scale. Business Opportunity Landscape: Where the Growth Lies C-suite leaders, investors, and business strategists eyeing the molecular infectious disease testing space should consider five high-potential opportunity zones: A. Horizontal Expansion into Adjacent Conditions Beyond traditional infectious diseases, molecular platforms are being adapted for oncology (viral-driven cancers), transplant monitoring, and immune dysfunction diagnostics. This expands addressable markets and strengthens platform utility. B. Strategic M&A and Licensing Models Smaller diagnostic innovators with novel amplification chemistries, miniaturized hardware, or AI overlays are ripe for acquisition or joint ventures. Corporates seeking to build comprehensive diagnostic ecosystems must prioritize these integrations. C. Private-Public Lab Collaborations Innovative partnerships between diagnostics firms and health agencies (local, federal, or international) will streamline test deployment in underserved geographies, leveraging pooled resources and shared logistics. D. Outcome-Based Reimbursement Models The shift to value-based care compels diagnostics providers to demonstrate impact on outcomes and cost avoidance. Firms that can link molecular testing to reduced admissions, antibiotic usage, or outbreak costs will command premium reimbursements. E. Supply Chain and Manufacturing Localization Post-pandemic disruptions underscore the value of regionalized manufacturing and agile logistics. Companies investing in decentralized, scalable production will enjoy lower lead times, geopolitical risk insulation, and margin protection. A Call to Action: Redefining the Diagnostic Future The evolution of Molecular Infectious Disease Testing represents more than a technological upgrade—it's a business imperative with the potential to redefine diagnostics, reshape public health response, and reimagine the value chain across healthcare. Senior executives who treat molecular testing as a strategic pillar—not a supplemental tool—will lead the industry's transformation. This moment requires bold investments, long-horizon vision, and operational agility. Whether you are a diagnostic innovator, a health system leader, a policy architect, or a life sciences strategist, the time to act is now. The trajectory is clear: the future of infectious disease testing is molecular, digital, decentralized, and intelligent. Those who move early, scale smartly, and innovate continuously will not only lead markets—they will help safeguard global health. For more information, Inquire Now!